Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Mar:17:16-17.
doi: 10.1016/j.ebiom.2017.02.023. Epub 2017 Feb 27.

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future

Cristoforo Incorvaia  1 , Gian Galeazzo Riario-Sforza  2 , Erminia Ridolo  3
Affiliations
Comment

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future

Cristoforo Incorvaia et al. EBioMedicine. 2017 Mar.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A. Sepharose-bound ScFv12 removes IgE produced by plasma cells so that it does not bind to basophils and mast cells. B. Omalizumab binds soluble IgE and prevents IgE binding to the high affinity receptor for IgE on mast cells and basophils. Omalizumab also prevents IgE binding to CD23 and thus inhibits binding to CD23-expressing B cells. C. Ligelizumab binds soluble IgE with higher affinity than Omalizumab and also neutralizes IgE on basophil surface. D. MEDI1412 neutralizes soluble IgE and eliminates IgE-expressing B-cells through ADCC.
See this image and copyright information in PMC

Comment on

  • Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.
    Lupinek C, Derfler K, Lee S, Prikoszovich T, Movadat O, Wollmann E, Cornelius C, Weber M, Fröschl R, Selb R, Blatt K, Smiljkovic D, Schoder V, Cervenka R, Plaichner T, Stegfellner G, Huber H, Henning R, Kozik-Jaromin J, Perkmann T, Niederberger V, Petkov V, Valent P, Gauly A, Leinenbach HP, Uhlenbusch-Koerwer I, Valenta R. Lupinek C, et al. EBioMedicine. 2017 Mar;17:119-133. doi: 10.1016/j.ebiom.2017.02.007. Epub 2017 Feb 12. EBioMedicine. 2017. PMID: 28254561 Free PMC article. Clinical Trial.

References

    1. Arm J.P., Bottili I., Skerianec A. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin. Exp. Allergy. 2014;44:1371–1385. - PMC - PubMed
    1. Chu S.Y., Horton H.M., Pong E. Reduction of total IgE by targeted co-engagement of IgE B-cell receptor and FcγRIib with FC-engineered antibody. J. Allergy Clin. Immunol. 2012;129:1102–1115. - PubMed
    1. Cohen E.S., Dobson C.L., Kack H. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014;6:756–764. - PMC - PubMed
    1. Gauvreau G.M., Arm J.P., Boulet L.P. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016;138:1051–1059. - PubMed
    1. Incorvaia C., Mauro M., Riario-Sforza G.G. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2:67–73. - PMC - PubMed